| Starts: | Thursday November 19, 2009 at 8:30am |
|---|---|
| Ends: | Thursday November 19, 2009 at 5:00pm |
| Event Type: | Conference |
| Region: | San Francisco Bay Area |
| Location: |
Claremont Resort and Spa 41 Tunnel Rd Berkeley, CA 94705 US |
| Price: | $199 ($99.50 academic) |
| Website: | http://lifescience.planetconnect.com/program/pmberkeley2009 |
| Industry: | biotechnology |
| Keywords: | Companion Diagnostics, Genetic Profile, Targeted Therapeutics, Cancer, Theranostics, Data Mining, Medical Device, Genomics, Biomarkers, Translational Medicine |
| Intended For: | researchers, bioinformaticians, product managers, business development, research strategy, licensing, IP, CSO, CEO, VP Research, Professor, Principal Investigator |
| Organization: | PlanetConnect |
Why you want to attend this meeting on targeted therapeutics and companion diagnostics:
The Experimental Man Project: The impact of biomarkers and personalized medicine on patients and consumers David Ewing Duncan Director, Center for Life Science Policy, UC Berkeley
An institute without walls to further collaborations in translational medicine for pediatric cancer Beth Anne Baber Co‐Founder, CEO, and President, The Nicholas Conor Institute for Pediatric Cancer Research
The Coming Age of Theranostics Amit Agarwal Partner, Scientia Advisors
Changing decision‐making in life sciences & personalized medicine: Applied Semantic Knowledgebases (ASK ®) at work! Erich A. Gombocz Vice President, Chief Scientific Officer, IO Informatics
Personalized and Painless: A Non-invasive Disease Detection and Companion Diagnostic Tool George Schwartz CEO, DermTech, and William Wachsman Associate Professor of Medicine, UC San Diego
Introducing the Genome Commons Steven Brenner Principal Investigator of the Genome Commons Associate Professor at the University of California, Berkeley
Frequency of somatic mutations in human tumors classified by embryonic origin of tissues: identification of developmental lineage‐specific oncogenes and tumor suppressors Adam Pavlicek Senior Principal Scientist in Computational Biology, Pfizer
Looking for cancer‐causing genes‐‐tumor vs. host? David W. Moskowitz, MD Chairman, Chief Executive Officer and Chief Medical Officer, GenoMed
Use of Protein‐based Biomarkers for acute setting diagnoses Ferran Prat Senior Director, Strategic Planning & Licensing, Biosite
Location: Claremont Resort and Spa, Berkeley, CA Cost $199 ($99.50 for academics) Contact: Rita Lim-Wilby rlim@planetconnect.com
Register at http://PersonlizedMed.EventBrite.com
This conference looks great, and I'm really looking forward to it. I don't think we're winning the War on Cancer yet, despite 40 years' of trying. It's still unclear how relevant the single-gene familial cancer syndromes like Rb and p53 (Li-Fraumeni) are to sporadic cancer. We're beginning to suspect that hundreds, if not thousands, of genes are involved, not just one or a few.
A conversation about healthcare, medicine, and what's possible. Jay M. Tenenbaum, Founder, Chairman, Chief Scientist, CollabRx, Inc. Few people have the vision and power to change the world. Marty Tenenbaum has the rare combination of proven business success, patient advocacy, wisdom, and charisma to engage all the players necessary to change healthcare. Marty suggested for his participation in the one-day symposium Advances Towards Personalized Medicine that instead of a podium presentation, we could have a conversation, a straight talk about what matters to enable the change we seek in discovering new therapeutics. PlanetConnect invites you to join in the conversation. Send your questions to RLim@planetconnect.com. If you do not wish to remain anonymous, include your name, affiliation, and contact information. Symposium website: http://lifescience.planetconnect.com/program/pmberkeley2009